II. Research: Studies

  1. Evaluation of 446 physicians surveyed
    1. Higher Prescribing Cost risks
      1. Pharmaceutical representative exposure
      2. Group practice setting
    2. References
      1. Caudill (1996) Arch Fam Med 5:201-6 [PubMed]
  2. Direct drug advertising to healthcare consumers
    1. Appears to increase sale of drugs
    2. May result in appropriate prescribing practices
    3. Mintzes (2002) BMJ 324:278-9 [PubMed]
  3. Pharmaceutical samples raise overall Prescribing Costs
    1. Symm (2006) J Am Board Fam Med 19(5): 443-9 [PubMed]
  4. Poorest patients are the least likely to receive free drug samples
    1. Typical drug sample recipient has health insurance and lives far above poverty line
    2. Cutrona (2008) Am J Public Health 98(2): 284-9 [PubMed]
  5. >25% ($16 billion) of drug company advertising ($57 billion) was spent on samples (2004)
    1. Gagnon (2008) PLoS Med 5(1): e1 [PubMed]

III. Precautions: Gifts

  1. Sunshine Act (U.S. regulation as of August 2013)
    1. Pharmaceutical representative gifts over $10 are reported to a public list (with the provider's name)

IV. Resources

  1. No Free Lunch
    1. http://nofreelunch.org

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window